Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
ABT-751
BCRP
MDR3
Melanoma
Multi-drug resistance
P-gp
Taxanes
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
28
07
2023
accepted:
20
11
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Drug efflux transporter associated multi-drug resistance (MDR) is a potential limitation in the use of taxane chemotherapies for the treatment of metastatic melanoma. ABT-751 is an orally bioavailable microtubule-binding agent capable of overcoming MDR and proposed as an alternative to taxane-based therapies. This study compares ABT-751 to taxanes in vitro, utilizing seven melanoma cell line models, publicly available gene expression and drug sensitivity databases, a lung cancer cell line model of MDR drug efflux transporter overexpression (DLKP-A), and drug efflux transporter ATPase assays. Melanoma cell lines exhibit a low but variable protein and RNA expression of drug efflux transporters P-gp, BCRP, and MDR3. Expression of P-gp and MDR3 correlates with sensitivity to taxanes, but not to ABT-751. The anti-proliferative IC Our study confirms that ABT-751 is active against melanoma cell lines and models of MDR at physiologically relevant concentrations, it inhibits P-gp ATPase activity, and it may be a BCRP and/or MDR3 substrate. ABT-751 warrants further investigation alone or in tandem with other drug efflux transporter inhibitors for hard-to-treat MDR melanoma.
Identifiants
pubmed: 38226983
doi: 10.1007/s00280-023-04624-6
pii: 10.1007/s00280-023-04624-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Science Foundation Ireland
ID : 20-SPP-3684
Pays : Ireland
Informations de copyright
© 2024. The Author(s).
Références
SEER*Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/statistics-network/explorer/
Ferlay J, Laversanne M, Ervik M, et al (2020) Global cancer observatory: cancer tomorrow. International Agency for Research on Cancer, Lyon. https://gco.iarc.fr/tomorrow
Switzer B, Puzanov I, Skitzki JJ et al (2022) Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract 18:335–351. https://doi.org/10.1200/op.21.00686
doi: 10.1200/op.21.00686
pubmed: 35133862
pmcid: 9810138
Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
doi: 10.1200/JCO.2000.18.1.158
pubmed: 10623706
Chapman PB, Einhorn LH, Meyers ML et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751
doi: 10.1200/JCO.1999.17.9.2745
pubmed: 10561349
Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194–204. https://doi.org/10.1038/nrc2803
doi: 10.1038/nrc2803
pubmed: 20147901
Pham JP, Joshua AM, da Silva IP et al (2023) Chemotherapy in cutaneous melanoma: is there still a role? Curr Oncol Rep 25:609–621. https://doi.org/10.1007/s11912-023-01385-6
doi: 10.1007/s11912-023-01385-6
pubmed: 36988735
pmcid: 10164011
Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33–40. https://doi.org/10.1124/jpet.112.192195
doi: 10.1124/jpet.112.192195
pubmed: 22454535
pmcid: 3383040
Shirley M (2018) Encorafenib and binimetinib: first global approvals. Drugs 78:1277–1284. https://doi.org/10.1007/s40265-018-0963-x
doi: 10.1007/s40265-018-0963-x
pubmed: 30117021
Qiu JG, Zhang YJ, Li Y et al (2015) Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget 6:15494–15509. https://doi.org/10.1863/oncotarget.3820
doi: 10.1863/oncotarget.3820
pubmed: 25915534
pmcid: 4558166
Choo EF, Ly J, Chan J et al (2014) Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm 11:4199–4207. https://doi.org/10.1021/mp500435s
doi: 10.1021/mp500435s
pubmed: 25243894
Berger W, Elbling L, Minai-Pour M et al (1994) Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int J Cancer 59:717–723
doi: 10.1002/ijc.2910590522
pubmed: 7960246
Walsh N, Kennedy S, Larkin AM et al (2010) Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Br J Cancer 102:1157–1162. https://doi.org/10.1038/sj.bjc.6605590
doi: 10.1038/sj.bjc.6605590
pubmed: 20234362
pmcid: 2853088
Lincke CR, Smit JJ, Van Der Velde-Koerts T, Borst P (1991) Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 266:5303–5310. https://doi.org/10.1016/s0021-9258(19)67788-4
doi: 10.1016/s0021-9258(19)67788-4
pubmed: 2002063
Januchowski R, Wojtowicz K, Andrzejewska M, Zabel M (2014) Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother 68:111–117. https://doi.org/10.1016/j.biopha.2013.09.004
doi: 10.1016/j.biopha.2013.09.004
pubmed: 24140176
Němcová-Fürstová V, Kopperová D, Balušíková K et al (2016) Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol 310:215–228. https://doi.org/10.1016/j.taap.2016.09.020
doi: 10.1016/j.taap.2016.09.020
pubmed: 27664577
Westover D, Li F (2015) New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res 34:1–9. https://doi.org/10.1186/s13046-015-0275-x
doi: 10.1186/s13046-015-0275-x
Monzani E, Facchetti F, Galmozzi E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946. https://doi.org/10.1016/j.ejca.2007.01.017
doi: 10.1016/j.ejca.2007.01.017
pubmed: 17320377
Wu C-P, Sim H-M, Huang Y-H et al (2013) Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol 85:325–334. https://doi.org/10.1016/j.bcp.2012.11.003
doi: 10.1016/j.bcp.2012.11.003
pubmed: 23153455
Hande KR, Hagey A, Berlin J et al (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12:2834–2840
doi: 10.1158/1078-0432.CCR-05-2159
pubmed: 16675578
Mauer AM, Cohen EEW, Ma PC et al (2008) A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 3:631–636. https://doi.org/10.1097/jto.0b013e318174e01f
doi: 10.1097/jto.0b013e318174e01f
pubmed: 18520803
Ma T, Fuld AD, Rigas JR et al (2012) A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy 58:321–329. https://doi.org/10.1159/000343165
doi: 10.1159/000343165
pubmed: 23147218
Fox E, Mosse’ YP, Meany HM, et al (2014) Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children’s Oncology Group (ANBL0621). Pediatr Blood Cancer 61:990–996. https://doi.org/10.1002/pbc.24900
doi: 10.1002/pbc.24900
pubmed: 24347462
Dehghanian SZ, Pan C-T, Lee JM, Shiue Y-L (2021) ABT-751 Induces multiple anticancer effects in urinary bladder urothelial carcinoma-derived cells: highlighting the induction of cytostasis through the inhibition of SKP2 at both transcriptional and post-translational levels. Int J Mol Sci 22:945. https://doi.org/10.3390/ijms22020945
doi: 10.3390/ijms22020945
pubmed: 33478005
pmcid: 7835924
Wei R, Wu W, Pan C et al (2019) Inhibition of the formation of autophagosome but not autolysosome augments ABT-751-induced apoptosis in TP53-deficient Hep-3B cells. J Cell Physiol 234:9551–9563. https://doi.org/10.1002/jcp.27643
doi: 10.1002/jcp.27643
pubmed: 30367486
Koyanagi N, Nagasu T, Fujita F et al (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54:1702–1706
pubmed: 8137285
Yoshimatsu K, Yamaguchi A, Yoshino H et al (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57:3208–3213
pubmed: 9242451
Clynes M, Redmond A, Moran E, Gilvarry U (1992) Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology 10:75–89
doi: 10.1007/BF00376102
pubmed: 1369413
Liang Y, O’Driscoll L, Mcdonnell S et al (2004) Enhancedin vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 111:484–493. https://doi.org/10.1002/ijc.20230
doi: 10.1002/ijc.20230
pubmed: 15239124
Ghandi M, Huang FW, Jané-Valbuena J et al (2019) Next-generation characterization of the cancer cell line encyclopedia. Nature 569:503–508. https://doi.org/10.1038/s41586-019-1186-3
doi: 10.1038/s41586-019-1186-3
pubmed: 31068700
pmcid: 6697103
Herlyn M, Balaban G, Bennicelli J et al (1985) Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74:283–289
pubmed: 3856042
Szakács G, Annereau J-P, Lababidi S et al (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129–137. https://doi.org/10.1016/j.ccr.2004.06.026
doi: 10.1016/j.ccr.2004.06.026
pubmed: 15324696
Jang SH, Wientjes MG, Au JL (2001) Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 298:1236–1242
pubmed: 11504826
Temesszentandrási-Ambrus C, Nagy G, Bui A, Gáborik Z (2023) A unique in vitro assay to investigate ABCB4 transport function. Int J Mol Sci 24:4459. https://doi.org/10.3390/ijms24054459
doi: 10.3390/ijms24054459
pubmed: 36901890
pmcid: 10003010
Mundra V, Li W, Mahato RI (2015) Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) 10:2613–2633. https://doi.org/10.2217/nnm.15.111
doi: 10.2217/nnm.15.111
pubmed: 26244818
Fuchs B, Ostmeier H, Suter L (1991) p-glycoprotein expression in malignant melanoma. J Cancer Res Clin Oncol 117:168–171
doi: 10.1007/BF01613142
pubmed: 1672531
Schadendorf D, Herfordt R, Czarnetzki BM (1995) P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 132:551–555
doi: 10.1111/j.1365-2133.1995.tb08710.x
pubmed: 7748745
Ichihashi N, Kitajima Y (2001) Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol 144:745–750. https://doi.org/10.1046/j.1365-2133.2001.04129.x
doi: 10.1046/j.1365-2133.2001.04129.x
pubmed: 11298532
Baker EK, Johnstone RW, Zalcberg JR, El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24:8061–8075. https://doi.org/10.1038/sj.onc.1208955
doi: 10.1038/sj.onc.1208955
pubmed: 16091741
Colone M, Calcabrini A, Toccacieli L et al (2008) The multidrug transporter p-glycoprotein: a mediator of melanoma invasion? J Investig Dermatol 128:957–971. https://doi.org/10.1038/sj.jid.5701082
doi: 10.1038/sj.jid.5701082
pubmed: 17943188
Wang Z, Chen J, Wang J et al (2012) Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res 29:3040–3052. https://doi.org/10.1007/s11095-012-0726-4
doi: 10.1007/s11095-012-0726-4
pubmed: 22410804
pmcid: 3659804
Liang Y, Li S, Chen L (2015) The physiological role of drug transporters. Protein Cell 6:334–350. https://doi.org/10.1007/s13238-015-0148-2
doi: 10.1007/s13238-015-0148-2
pubmed: 25797421
pmcid: 4417677
Frost D, Refici M, Joseph I et al (2007) ABT-751, an oral antimitotic, shows additive and synergistic activity with docetaxel in preclinical models. Can Res 67:1426
Pochampally S, Hartman KL, Wang R et al (2023) Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer activity both in vitro and in vivo. ACS Pharmacol Transl Sci 6:526–545. https://doi.org/10.1021/acsptsci.2c00108
doi: 10.1021/acsptsci.2c00108
pubmed: 37082747
Janavicius M, Lachej N, Anglickiene G et al (2020) Outcomes of treatment for melanoma brain metastases. J Skin Cancer 2020:7520924. https://doi.org/10.1155/2020/7520924
doi: 10.1155/2020/7520924
pubmed: 33282420
pmcid: 7685861